Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have consistently shown superior efficacy and safety compared to platinum-based chemotherapy in multiple phase 3 trials,4,5,6,7,8,9,10 establishing the standard first-line treatment for patients with EGFR-variant advanced NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.